UNSPSC 51342802: Atevirdine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N24015WC6D chemically known as piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1h-indol-2-yl)carbonyl)-, monomethanesulfonate but generally known as atevirdine, which bears US NIH Compound Identifier 60848. European Medicines Agency schedules Atevirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05591MIG.

UNSPSC 51342802 Atevirdine (Commodity) does not reflect meaningful recent state and local procurement activity. The two opportunities tagged to this code in the recent activity block involve unrelated pharmaceutical products—doxycycline hyclate and ciprofloxacin hydrochloride tablets in one instance, and naloxone and drug deactivation systems in another—neither of which corresponds to atevirdine, an antiviral medication. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic supply, while Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and deactivation systems with a July 26, 2023, response deadline. These misaligned classifications suggest either tagging errors in the underlying procurement database or minimal genuine demand for atevirdine through state and local channels.

Without correctly classified opportunities, no reliable picture of issuing-body mix, geographic concentration, or representative work scope can be drawn from this code. A business development professional evaluating pursuit should treat this code as dormant and investigate whether atevirdine procurement activity appears under alternative UNSPSC classifications or through direct outreach to state health departments and county health systems.